ByteDance's Anew Labs Hits $1.5B in AI Drug Bet

ByteDance, the company the world knows for TikTok and the recommendation algorithm that reshaped global attention, just placed its biggest bet yet on something far removed from short video: inventing new medicines. On Wednesday, the Chinese tech giant completed a $290 million inaugural fundraising for Anew Labs, its AI drug-discovery unit, valuing the freshly spun-off company at $1.5 billion, according to two people with knowledge of the matter cited by Reuters.

The deal, led by HSG — the firm formerly known as Sequoia China — alongside IDG Capital and Hillhouse Investment, with 5Y Capital as co-lead, instantly makes Anew Labs one of the best-funded AI drug-discovery startups on the planet. And it signals something larger than one financing: the AI industry's center of gravity is shifting, and drug discovery has become one of its most fiercely contested frontiers.

Illustration of a robotic AI-assisted pharmaceutical research laboratory with molecular structures

The deal, by the numbers

Here is what Reuters reported on September 16, confirmed by two sources speaking on condition of anonymity because the information is not yet public:

Shanghai-headquartered Anew Labs raised $290 million in its first external financing, reaching a $1.5 billion valuation. The round was led by HSG, IDG Capital and Hillhouse Investment, with 5Y Capital joining as co-lead investor. The syndicate also includes Gaorong Ventures, Primavera Venture Partners and Boyu Capital, plus strategic investor SBP Group and the state-backed Shanghai Future Industries Fund.

ByteDance retains a 56% stake after the fundraising, keeping majority control while giving the unit the outside capital and independent governance it needs to operate like a biotech company rather than a division of a social media giant.

Neither ByteDance nor the investors immediately responded to Reuters' requests for comment.

Why spin it off at all

The rationale, per one of Reuters' sources, is structural: AI drug discovery follows a different industry logic and management approach than ByteDance's core operations. That is a polite way of describing a real tension. A company optimized for shipping consumer apps on quarterly cycles is poorly shaped for work where a single molecule can take a decade and a billion dollars to reach patients — and where failure is the default outcome.

Spinning Anew Labs out solves several problems at once. It lets the unit hire scientists and executives with biotech compensation structures, pursue partnerships with pharmaceutical companies that might hesitate to share data with TikTok's parent, and raise dedicated capital from investors who understand drug-development timelines. It also insulates ByteDance's core business from the regulatory and reputational scrutiny that follows anything touching human health.

The pattern is familiar in American tech. Google's parent Alphabet spun its own AI drug-discovery effort, Isomorphic Labs, out of DeepMind in 2021. Isomorphic raised $600 million in March 2025 in a round led by Thrive Capital with participation from GV and Alphabet, and followed it with a $2.1 billion raise in May 2026, again led by Thrive. ByteDance appears to be running the same playbook, five years later and with Chinese capital.

Who is betting — and what that reveals

The investor roster is a statement in itself. HSG, IDG Capital and Hillhouse are among the most formidable names in Chinese venture capital, and their joint presence suggests Anew Labs was a competitive round, not a quiet insider financing. The participation of the state-backed Shanghai Future Industries Fund adds a policy dimension: Beijing has made no secret of wanting domestic champions in AI-driven life sciences, a field where the United States and Britain currently lead.

That makes Anew Labs a new data point in a technology race Washington is watching closely. The U.S. has Isomorphic Labs in London, Xaira Therapeutics — which raised $1 billion in its Series A — and a cluster of well-funded AI-biotech startups in Boston and San Francisco. China now has a $1.5 billion entrant with ByteDance's compute infrastructure and AI talent behind it.

Illustration of a glowing DNA helix and drug molecule above a city skyline at dusk

Why drugs, why now

Drug discovery is arguably the most natural application of modern AI outside of language. The industry's core problem is search: out of a near-infinite space of possible molecules, find the handful that bind to a disease target, survive the body's chemistry, and can be manufactured at scale. Machine learning models — most famously DeepMind's AlphaFold, which predicts protein structures — have begun to collapse timelines that once took years of trial and error into weeks of computation.

The economics are compelling. Developing a single new drug has historically cost well over $1 billion, with the vast majority of candidates failing in clinical trials. If AI can meaningfully raise the hit rate — even modestly — the returns are enormous. That math has drawn a flood of capital: AI-biotech was one of the few venture categories to stay hot through the broader startup funding chill.

But the field has also produced cautionary tales. Recursion Pharmaceuticals, an early AI-drug-discovery darling, has seen its shares fall roughly 90% from its 2021 listing as investors questioned the gap between algorithmic promise and clinical results. Britain's BenevolentAI was taken private last year. The lesson, which Anew Labs' backers surely understand, is that AI can accelerate discovery but cannot repeal biology. Molecules still have to work in humans.

The Science: Cracking the 'Undruggable' IL-17 Protein

The most interesting molecule in Anew Labs' pipeline has nothing to do with the financing — and everything to do with why the company exists. Its lead candidate is a small-molecule inhibitor of IL-17, a protein behind chronic inflammation in conditions such as psoriasis and rheumatoid arthritis. It is still preclinical, in lead optimization, but the ambition is plain: a pill that does what today's IL-17 drugs do only by injection.

That is a harder problem than it sounds. The drugs that dominate the IL-17 market — Novartis' Cosentyx and Eli Lilly's Taltz — are injectable antibodies, and even the strongest dual-target antibody covers only two of the IL-17 family's three dimers. Anew's candidate is designed as a pan-IL-17 small molecule, engaging all three dimers at once. The reason nobody has done it before is structural: IL-17 meets its receptor across a broad, flat protein-protein interface that gives conventional small molecules almost nothing to grip, which is why the industry long filed this class of target under "undruggable." Anew presented its first data on the candidate in April 2026 at the American Association of Immunologists' annual meeting in Boston.

The platform behind it is the other half of the story. AnewFold predicts protein and molecular-complex structures; AnewDesign optimizes antibody design; AnewMind is a reasoning model that assists drug-discovery decisions. Beyond IL-17, the pipeline lists an IL-4 receptor program and two undisclosed targets. None of this is a drug yet — lead optimization is the long, failure-prone middle of discovery, not the end of it — but it is the clearest evidence that Anew Labs is a science company first and a financing story second.

What it means for the United States

For American readers, the Anew Labs spin-off lands in an already crowded strategic picture. The U.S. leads in AI drug discovery today, but the lead is not comfortable. China's advantages — vast patient datasets, lower trial costs, and now state-coordinated capital — are real. A ByteDance-backed, HSG-funded Anew Labs will compete directly with American and European firms for scientific talent, pharmaceutical partnerships, and ultimately the drugs themselves.

There is also a subtler dynamic. ByteDance's AI capabilities, honed on recommendation systems and large language models, transfer surprisingly well to molecular design: both are, at bottom, pattern-recognition problems at massive scale. The same infrastructure that serves a billion TikTok users can screen billions of compounds. That is the industrial logic behind the spin-off, and it is why this $290 million round deserves more attention than a typical venture financing.

It is worth noting the parallel with the broader AI moment. Just this week, Factory AI tripled to a $5 billion valuation on the strength of AI coding agents. Capital is pouring into applied AI at a pace that would have been unthinkable three years ago. Drug discovery is simply the highest-stakes application of the same wave.

What to watch

Three questions will determine whether Anew Labs justifies its $1.5 billion price tag. First, leadership: the company will need drug-discovery veterans, not just AI researchers, and its hiring in the coming months will be revealing. Second, partnerships: Isomorphic Labs validated itself through deals with Eli Lilly and Novartis worth up to $3 billion in milestones. Anew Labs will need its own pharma alliances to prove its platform works on real targets. Third, the pipeline: the ultimate test is molecules in human trials, and that takes years.

For now, the financing itself is the news — and it is substantial. A $290 million first external round is not a seed bet. It is a declaration that one of the world's largest technology companies believes AI-designed drugs are close enough to matter, and is willing to build a $1.5 billion company to prove it.

Sources: Reuters (Sept. 16, 2026, reporting by Kane Wu); TechCrunch; Crunchbase News; Sifted.

Search This Blog

TechPulse USA